ADC Therapeutics Shares Decline Following Lymphoma Drug Trial Results

ADC Therapeutics saw its stock price decrease significantly today in the wake of new clinical trial data concerning its lymphoma therapy, Zynlonta. The company had been progressing with a Phase 3 confirmatory study for the treatment, which is designed to combat diffuse large B-cell lymphoma (DLBCL). According to Seeking Alpha, the trial, known as the LOTIS 9 study, aimed to determine the effectiveness of Zynlonta in combination with rituximab. This particular regimen was being investigated as a potential second-line treatment, administered in cycles for up to a year, targeting patients whose initial treatment for DLBCL had proven unsuccessful but whose disease had not yet progressed. The essential objective of the LOTIS 9 trial was to observe if the combined Zynlonta and rituximab treatment demonstrated superiority in efficacy compared to a standard R-chemo regimen, which is a common chemotherapy approach also incorporating rituximab. The primary measure for success was progression-free survival (PFS), meaning the length of time a patient lives with the disease without it worsening. However, the outcomes of the study indicated that the Zynlonta combination did not achieve the anticipated improvement in progression-free survival when compared to the R-chemo control group. This outcome falls short of the prespecified success criteria for the trial, which had critical implications for the company and its future plans for the therapy. Zynlonta (loncastuximab tesirine-lpyl) is an antibody-drug conjugate (ADC) that targets CD19, a protein found on lymphoma cells. It had previously received accelerated approval from regulatory bodies for the treatment of adult patients with relapsed or refractory DLBCL, based on earlier promising data. The accelerated approval was contingent upon the company conducting and verifying the clinical benefit through a confirmatory trial, such as the LOTIS 9 study. The recent trial results raise questions about the broader application and market expansion of Zynlonta, particularly regarding its use in earlier lines of treatment for DLBCL. The company’s stock performance often reflects investor confidence in its pipeline and the commercial potential of its approved and experimental drugs.